Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26. https://doi.org/10.1002/art.39480.

Article  PubMed  Google Scholar 

Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183–96. https://doi.org/10.1016/j.immuni.2017.02.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–8. https://doi.org/10.1016/j.semarthrit.2006.08.006.

Article  PubMed  Google Scholar 

Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633–9. https://doi.org/10.1002/art.30155.

Article  PubMed  PubMed Central  Google Scholar 

Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Protocolo Clínico e Diretrizes Terapêuticas da Artrite Reumatóide . Brasília: Ministério da Saúde; 2020. Available from: http://conitec.gov.br/images/Consultas/Relatorios/2020/Relatrio_Artrite_Reumatoide_CP_21_2020.pdf. 2020.

World Organization Health (WHO). Glossário com definições da Organização Mundial de Saúde. International Alliance of Patients Organizations. Biored Brasil. 2016. Available from: https://www.bioredbrasil.com.br/glossario-com-definicoes-da-organizacao-mundial-da-saude-oms/#:~:text=Medicamentos.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75. https://doi.org/10.1136/ard.2009.126532. Epub 2010 May 5. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519

Sigurdardottir V, Svärd A. Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months - a cohort study with historical controls. Joint Bone Spine. 2019;86(4):529–30. https://doi.org/10.1016/j.jbspin.2018.12.003.

Article  PubMed  Google Scholar 

Gomes E, Rosseto R, Pinheiro L, Hasenclever L, Paranhos J. Desenvolvimento de Biossimilares no Brasil. Front J Soc Technol Environ Sci. 2016;5(1):31–42. Available from: http://periodicos.unievangelica.edu.br/index.php/fronteiras/.

Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–7. https://doi.org/10.1182/blood-2012-04-425744.

Article  CAS  PubMed  Google Scholar 

Niazi SK. Biosimilars and Interchangeable Biologics: Tactical Elements. Boca Raton: CRC Press, Taylor & Francis Group: CRC Press, Taylor & Francis Group; 2016. 575 p.

Mota, L.M.H.d., Kakehasi, A.M., Gomides, A.P.M. et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol (London, England). 2018;58(1):2. https://doi.org/10.1186/s42358-018-0005-0.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100.

Article  PubMed  PubMed Central  Google Scholar 

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35. https://doi.org/10.1002/art.1780380602.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Higgins JPT, Sterne JAC, Savović J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database of Systematic Reviews. 2016;Issue 10(Suppl 1). https://doi.org/10.1002/14651858.CD201601.

Brasil. Diretrizes metodológicas: Sistema GRADE – Manual de graduação da qualidade da evidência e força de recomendação para tomada de decisão em saúde. Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia. – Brasília: Ministério da Saúde, 2014. 72f. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_sistema_grade.pdf.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.

Article  PubMed  Google Scholar 

Bae SC, Kim J, Choe JY, Park W, Lee SH, Park YB, et al. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2017;76(1):65–71. https://doi.org/10.1136/annrheumdis-2015-207613.

Article  CAS  PubMed  Google Scholar 

Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015;76(1):51–7. https://doi.org/10.1136/annrheumdis-2015-207588.

Article  CAS  PubMed  Google Scholar 

Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, Tseluyko V, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017;56(12):2093–101. https://doi.org/10.1093/rheumatology/kex269.

Article  CAS  PubMed  Google Scholar 

Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Stasiuk B, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986–91. https://doi.org/10.1136/annrheumdis-2017-211591.

Article  CAS  PubMed  Google Scholar 

Jaworski J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, Kucharz EJ, Allanore Y, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019;21(1):130. https://doi.org/10.1186/s13075-019-1907-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsuno H, Tomomitsu M, Hagino A, Shin S, Lee J, Song YW. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488–94. https://doi.org/10.1136/annrheumdis-2017-212172.

Article  CAS  PubMed  Google Scholar 

Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018;4(2):e000757. https://doi.org/10.1136/rmdopen-2018-000757.

Article  PubMed  PubMed Central  Google Scholar 

Park MC, Matsuno H, Kim J, Park SH, Lee SH, Park YB. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther. 2019;21(1):122. https://doi.org/10.1186/s13075-019-1910-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa JO, Lemos LLP, Machado MAA, Almeida AM, Kakehasi AM, Araújo VE et al . Infliximabe, metotrexato e sua combinação no tratamento da artrite reumatoide: revisão sistemática e metanálise. Rev Bras Reumatol. 2015;55(2):146–158. https://doi.org/10.1016/j.rbr.2014.10.009.

Machado, Marina Amaral de Ávila et al. Adalimumabe no tratamento da artrite reumatoide: uma revisão sistemática e metanálise de ensaios clínicos randomizados. Revista Brasileira de Reumatologia. 2013, v. 53, n. 5, pp. 419–430. Available from: <>. Epub 23 May 2014. ISSN 1809–4570.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii-iv, xi-xiii, 1–229. https://doi.org/10.3310/hta10420.

Navarro-Sarabia F, Ariza-Ariza R, Hernández-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J Rheumatol. 2006;33(6):1075–81 (Epub 2006 May 1).

CAS  PubMed  Google Scholar 

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE. 2012;7(1):e30275. https://doi.org/10.1371/journal.pone.0030275.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;17(9):52. https://doi.org/10.1186/1471-2474-9-52.

Article  Google Scholar 

Santos EJF, Cunha M. Interpretação Crítica dos Resultados Estatísticos de uma Meta‐Análise: Estratégias Metodológicas. Millenium, 2013;0(44):85‐98.

Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, et al. Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol. 2018Sep;70(9):1408–18. https://doi.org/10.1002/art.40516.

Article  CAS  PubMed  Google Scholar 

Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–31. https://doi.org/10.1136/annrheumdis-2016-210742.

Article  CAS  PubMed  Google Scholar 

Lee YJ, Shin D, Kim Y, Kang J, Gauliard A, Fuhr R. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol. 2016;82(1):64–73. https://doi.org/10.1111/bcp.12929.